Moderna announced Tuesday that it will begin testing its coronavirus vaccine on children barely 6 months of age.
Moderna’s trial will include some 7,000 children aged 6 months to 12 years from U.S. and Canada,.
Dr. Jacqueline Miller, a pediatrician and Moderna’s therapeutic area head for infectious diseases, told Good Morning America, said “there will be two parts to the study. The first part is where we will find the appropriate dose of the vaccine.”
She explained that “children often need lower doses of vaccines than adults and we want to make sure we find the best dose that increases their immunity.”
According to the company, the first age group to start in the trial will be children ages 6 to 11, followed by children ages 2 to 6 and then children 6 months to 2 years of age.
Both Moderna and Pfizer vaccines were given emergency use authorization from the FDA in December. The two pharmaceutical companies have enrolled children 12 and older in clinical trials of their vaccines and hope to have results by the summer.
Johnson & Johnson, however, has yet to announce plans to test its vaccine in children.